Phylex Biosciences

is a next-generation vaccine company uniquely located at
the crossroads of information technology and biotechnology.

We are developing the first multivalent vaccine against the SARS coronavirus. Our vaccine is designed to protect not only against SARS-CoV-2 (COVID-19), the virus at the origin of the current pandemic, but also against the variants in circulation responsible for increased transmissibility or pathogenicity.